ClinicalTrials.gg
Active, not recruitingNCT03901001Updated Oct 20, 2026

Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza

A Phase 3 interventional study of sirolimus and oseltamivir and Oseltamivir in Influenza, sponsored by Chinese University of Hong Kong. Active, not recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Chinese University of Hong Kong · Phase 3, Interventional, and Treatment

How we know

Updated Oct 20, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing oseltamivir in Influenza, Human — 3 open to participants now, 5 under way, 3 of them phase 3. Oseltamivir · Influenza, Human.

Planned enrollment
24th of 58
160 · median 118
Started
2023
with 1 other
Phase 3
10 of 59
1 open now
Registered
54th of 59
by date
Lead sponsor
3 of 59
Chinese University of Hong Kong

Among the 59 studies testing oseltamivir in Influenza, Human, this one is the 24th largest by planned enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2023, is one of 10 in phase 3, and was the 54th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 59 studies testing oseltamivir in Influenza, Human are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About oseltamivir

Oseltamivir: first FDA approval 1999 (TAMIFLU), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing oseltamivir in Influenza, Human, or all of them as a file.
02

Study summary

Seasonal influenza epidemics are important causes of mortality and morbidity. Cytokine dysregulation, with high levels of pro-inflammatory cytokines, occurs in patients with severe influenza A(H1N1)pdm09 virus infection, A(H5N1) infection, and A(H7N9) infection. We aim to investigate the effects of adjunctive sirolimus in adults hospitalized with influenza A or B infections involving the lower respiratory tract.

Read the detailed description

The investigators aim to investigate the effects of adjunctive sirolimus in adults hospitalized with influenza A or B infections involving the lower respiratory tract. Patients will be randomized to either oseltamivir and adjunctive sirolimus or oseltamivir alone and assessed with reference to normalization of respiratory status (SaO2 ≥93% or respiratory rate ≤20/min on room air) as the primary endpoint,10 cytokines/chemokines and pro-inflammatory mediator changes, viral clearance, symptom resolution, ICU admission/death, day 28 mortality; safety profiles will also be assessed.

The investigators hypothesize that addition of sirolimus to oseltamivir would improve respiratory status and other endpoints more effectively than oseltamivir alone through reduction of inflammatory responses without affecting viral clearance.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • respiratory
  • Mortality
  • cytokines
  • chemokines
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • influenza A and B virus infections confirmed by PCR and/or immunofluorescence assays, hospitalized for the management of severe manifestations of influenza, initiation of oseltamivir, clinical evidence of lower respiratory tract infection (e.g. shortness of breath, tachypnea, oxygen desaturation, crepitations on auscultation, infiltrations or consolidations on chest radiograph) and written (by the subjects, or from their next of kin if the subjects are unable to provide written consent at the time of enrollment)

Exclusion criteria

Exclusion Criteria:

  • use of other (e.g. post-chemotherapy, post-transplant, diseases) other than systemic
  • patients with known immuno-compromised conditions (e.g. active haematological , /AIDS patients who are on antiretroviral therapy and \< 200)
  • pregnancy/lactation
  • hepatic failure
  • patients with surgery done/planned within 1 month
  • patients who have received macrolide antibiotics and NSAID for 1 week prior to enrolment due to their immuno-modulating effects
  • patients on drugs that may interact and alter sirolimus level (rifampicin, azole antifungals, phenytoin, diltiazem, verapamil, nicardipine, metoclopramide, phenobarbital, carbamazepine) will be excluded for safety purposes
  • Use of anti-influenza antivirals and blood products
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    oseltamivir and adjunctive sirolimus

    Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

    Drug: sirolimus and oseltamivir

  • Placebo comparator
    oseltamivir alone

    oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

    Drug: Oseltamivir

Interventions

  • Drugsirolimus and oseltamivir

    Drug pages: SirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · OseltamivirStudies of OseltamivirOseltamivir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

  • DrugOseltamivir

    oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.

06

What researchers measure

Primary outcomes

  1. normalisation of respiratory status

    SaO2 ≥93% or respiratory rate ≤20/min on room air

    Time frame: 28 days

Secondary outcomes

  1. viral ribonucleic acid (RNA) in copies per milliliter

    All serially collected samples will be subjected to viral ribonucleic acid (RNA) quantification using quantitative reverse transcription PCR (qRTPCR) targeting the matrix (M)-gene ('viral load')

    Time frame: 28 days

  2. Interleukin 6 in pg/ml

    Time frame: 10 days

  3. interleukin-8 in pg/ml

    Time frame: 10 days

  4. interleukin 17 in pg/ml

    Time frame: 10 days

  5. Chemokine ligand 9 (CxCL9/MIG) in pg/ml

    Time frame: 10 days

  6. Soluble tumour necrosis factor receptor-1 (sTNFR-1) in pg/ml

    Time frame: 10 days

  7. interleukin 18 in pg/ml

    Time frame: 10 days

  8. CRP in mg/L

    Time frame: 10 days

  9. phospho-p38 and phospho-ERK (activated MAPKs) in mean fluorescence intensity(MFI)

    Time frame: 10 days

  10. phospho-inhibitor kB/IkB (NF-kB) in mean fluorescence intensity(MFI)

    Time frame: 10 days

  11. resolution of symptoms in days

    A standard questionnaire will be used to collect baseline and serial clinical data. These include clinical manifestations/complications, symptom severity score, vital signs (e.g. temperature, respiratory rate, oxygen saturation), fever duration, requirements for supplemental oxygen therapy and invasive/non-invasive ventilation, duration of hospitalization, death, and occurrence of adverse events.

    Time frame: 28 days

  12. ICU admission in days

    Time frame: 28 days

  13. mortality in days

    Time frame: 28 days

  14. Incidence of Treatment-Emergent Adverse Events in numbers

    Time frame: 28 days

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in May 2026, 36 months.

Of 35 non-industry phase 3 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's 36 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Oct 2025 → May 2026 and completion Dec 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2019
First posted
Apr 3, 2019
StartActual
May 8, 2023
Primary completionActual
May 16, 2026was Oct 2025
CompletionEst.
Dec 31, 2026was Dec 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Primary completion
Oct 31, 2025→May 16, 2026 (actual)
Oct 20, 2026
Study completion
Dec 31, 2025→Dec 31, 2026
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 31, 2025→May 16, 2026 (now actual)
    Study completion Dec 31, 2025→Dec 31, 2026
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03901001
Responsible party
Prof David Shu Cheong Hui (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Apr 3, 2019
Start date
May 8, 2023
Primary completion
May 16, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Oct 20, 2026

Study contacts

David SC Hui
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Oseltamivir

Start the discussion